MarketCap
Facebook
X
Telegram
Humanigen Total Shareholders Equity | HGEN
Annual Total Shareholders Equity Humanigen
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -46.8 M | -23.7 M | 45.5 M | -14.3 M | -8.11 M | -24.3 M | -4.38 M | 5.73 M | 24.6 M | 60.5 M | -94.9 M | -72.3 M | -70.4 M | -65.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 60.5 M | -94.9 M | -20.6 M |
Quarterly Total Shareholders Equity Humanigen
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -49.7 M | -46.8 M | -52.4 M | -50.1 M | -25 M | -23.7 M | -17.6 M | 43.7 M | 17 M | 45.5 M | 77.3 M | 31.6 M | -16.3 M | -14.3 M | -12.7 M | -10.8 M | -9.55 M | -8.11 M | -6.69 M | -7.07 M | -5.41 M | -24.3 M | -21.6 M | -14.7 M | -8.87 M | -4.38 M | -185 K | 4 M | 308 K | 5.73 M | 4.14 M | 10.5 M | 16.1 M | 24.6 M | 33.8 M | 41.4 M | 50.7 M | 60.5 M | 38.3 M | 49.1 M | 60.3 M | -94.9 M | -83.5 M | -75.4 M | -94.9 M | -72.3 M | -72.3 M | -72.3 M | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 77.3 M | -94.9 M | -7.95 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
103 M | $ 5.32 | 0.09 % | $ 652 M |  USA |
 |
ADC Therapeutics SA
ADCT
|
-186 M | $ 1.05 | 0.46 % | $ 133 M |  Schweiz |
 |
Agenus
AGEN
|
-271 M | $ 7.21 | 0.7 % | $ 214 M | USA |
 |
Akebia Therapeutics
AKBA
|
32.6 M | $ 0.92 | 1.64 % | $ 237 M | USA |
 |
Alector
ALEC
|
30.6 M | $ 1.93 | 0.81 % | $ 199 M | USA |
 |
Amryt Pharma plc
AMYT
|
357 M | - | - | $ 621 M |  Britain |
 |
Aligos Therapeutics
ALGS
|
53.5 M | $ 5.05 | 1.2 % | $ 49.9 M | USA |
 |
Alkermes plc
ALKS
|
1.82 B | $ 46.07 | 0.09 % | $ 7.59 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
293 M | $ 1.69 | 0.58 % | $ 373 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
789 M | $ 239.36 | 0.46 % | $ 31.4 B | USA |
 |
Altimmune
ALT
|
225 M | $ 3.24 | 0.31 % | $ 285 M | USA |
 |
ALX Oncology Holdings
ALXO
|
26 M | $ 1.76 | 0.53 % | $ 94.4 M | USA |
 |
Evelo Biosciences
EVLO
|
-4.99 M | - | -14.46 % | $ 27.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 23.95 | 1.31 % | $ 1.12 B | USA |
 |
AnaptysBio
ANAB
|
37.2 M | $ 54.31 | 0.15 % | $ 1.56 B | USA |
 |
Anika Therapeutics
ANIK
|
143 M | $ 20.84 | 0.24 % | $ 299 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
541 M | $ 73.59 | 2.05 % | $ 1.48 B | USA |
 |
Aptevo Therapeutics
APVO
|
17.4 M | $ 1.72 | 0.58 % | $ 543 K | USA |
 |
Allakos
ALLK
|
78.8 M | - | - | $ 28.6 M | USA |
 |
Aquestive Therapeutics
AQST
|
-33.7 M | $ 4.82 | 0.21 % | $ 515 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
214 M | $ 15.6 | 0.25 % | $ 427 M |  Israel |
 |
Armata Pharmaceuticals
ARMP
|
-219 M | $ 4.07 | 2.21 % | $ 147 M | USA |
 |
Assembly Biosciences
ASMB
|
207 M | $ 25.48 | 0.54 % | $ 286 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
7.83 M | $ 1.24 | 0.79 % | $ 38.7 M | USA |
 |
AbbVie
ABBV
|
-3.27 B | $ 262.51 | 0.01 % | $ 464 B | USA |
 |
Atara Biotherapeutics
ATRA
|
-38.5 M | $ 10.11 | 7.1 % | $ 127 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
581 M | $ 16.96 | 5.15 % | $ 2.28 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
178 M | $ 1.87 | 0.53 % | $ 498 M | Britain |
 |
Atea Pharmaceuticals
AVIR
|
275 M | $ 5.15 | 1.24 % | $ 420 M | USA |
 |
Axon Enterprise
AXON
|
3.24 B | $ 468.42 | 5.96 % | $ 36.6 B | USA |
 |
Axsome Therapeutics
AXSM
|
88.3 M | $ 211.97 | 3.87 % | $ 10.5 B | USA |
 |
Aytu BioScience
AYTU
|
19 M | $ 1.97 | 0.5 % | $ 12.4 M | USA |
 |
BridgeBio Pharma
BBIO
|
-2.09 B | $ 68.3 | 0.1 % | $ 13.1 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
610 M | $ 3.64 | 0.68 % | $ 252 M | Britain |
 |
Black Diamond Therapeutics
BDTX
|
112 M | $ 1.94 | 1.02 % | $ 110 M | USA |
 |
Beam Therapeutics
BEAM
|
1.24 B | $ 23.1 | 0.15 % | $ 2.28 B | USA |
 |
Biogen
BIIB
|
18.3 B | $ 216.01 | 0.42 % | $ 31.6 B | USA |
 |
BioLineRx Ltd.
BLRX
|
23.3 M | $ 2.48 | 0.79 % | $ 6.11 B | Israel |
 |
AbCellera Biologics
ABCL
|
967 M | $ 11.67 | 2.28 % | $ 3.49 B | Canada |
 |
Benitec Biopharma
BNTC
|
177 M | $ 11.04 | 0.9 % | $ 514 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
 |
Burford Capital Limited
BUR
|
2.45 B | $ 3.87 | 0.8 % | $ 848 M | Britain |
 |
Clovis Oncology
CLVS
|
-279 M | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
122 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
112 M | - | - | $ 401 M | USA |
 |
Cabaletta Bio
CABA
|
112 M | $ 2.49 | 0.39 % | $ 250 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 2.24 | 0.89 % | $ 3.69 M | Israel |
 |
Catalyst Biosciences
CBIO
|
106 M | $ 17.18 | 1.7 % | $ 1.53 B | USA |
 |
C4 Therapeutics
CCCC
|
257 M | $ 3.45 | 0.58 % | $ 286 M | USA |